The National Institute of Allergy and Infectious Diseases (NIAID) recently funded two new clinical trials to help address the growing threat of antimicrobial resistance by investigating the effectiveness of shorter antimicrobial regimens.
Children’s Hospital of Philadelphia was awarded $1.5 million to study children with urinary tract infections to determine if treatment with antimicrobials can be shortened and still be effective. The hospital will enroll up to 1,000 children in the study. Duke University in Durham, N.C., received $1.4 million for a project testing the effectiveness of shorter antimicrobial regimens for hospitalized patients who acquire staphylococcal bloodstream infections following the use of intravenous catheters. Both institutions can qualify for additional funding if milestones are met during the six-year NIAID contracts.
IDSA has been a strong advocate for funding this type of research. In 2007, in response to NIAID’s request for suggestions for studies that would help clarify the optimal antimicrobial therapy for common infectious diseases, IDSA submitted proposals for research focused on this issue. NIAID subsequently released a Broad Agency Announcement (BAA) in 2009 seeking proposals for targeted clinical trials to reduce antimicrobial resistance. The agency has continued this funding for 2010.
NIAID continues to solicit proposals for research to find improved treatment strategies that help minimize the development of antibiotic resistance, including research projects on acute ear infections in children, pneumonia, and bloodstream infections caused by gram-negative bacteria. For more information about NIAID opportunities, visit this page.
< Previous Article | Next Article >